Loading...
XSHE300294
Market cap1.99bUSD
Jan 16, Last price  
28.97CNY
1D
-0.31%
1Q
-13.13%
Jan 2017
-22.88%
IPO
205.45%
Name

China Resources Boya Bio pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300294 chart
P/E
61.52
P/S
5.51
EPS
0.47
Div Yield, %
0.92%
Shrs. gr., 5y
3.63%
Rev. gr., 5y
2.12%
Revenues
2.65b
-3.87%
90,168,286119,723,394141,823,513196,724,566227,259,439245,278,066437,792,952543,182,670946,596,0991,460,521,8562,387,519,4942,760,925,0462,513,038,6872,650,528,4212,758,701,3152,651,979,506
Net income
237m
-45.06%
10,713,30931,478,63649,976,47065,234,07175,146,19082,403,126104,179,698151,798,745272,041,808356,588,468469,174,808426,146,775260,060,146344,528,999432,197,553237,465,593
CFO
642m
+7.59%
051,879,91224,765,99881,527,03592,361,58089,106,522121,884,584147,018,107198,756,138034,902,7260718,583,0481,345,377,085596,437,198641,727,504
Dividend
Apr 26, 20240.3 CNY/sh

Profile

China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the blood products, diabetes medication, biochemical medication, and chemical medicine businesses in China. It engages in the research and development, production, and sales of blood products comprising human fibrinogen, intravenous human immunoglobulin, rabies immunoglobulin, human albumin, human immunoglobulin, freeze-dried intravenous human immunoglobulin, and hepatitis B human immunoglobulin; diabetes products, including metformin hydrochloride tablets/enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules; and compound osteotide, oxytocin, and heparin sodium injections for various fields, such as medicine, hepatitis, gynecology, and immunomodulation. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co., Ltd. China Resources Boya Bio-pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Fuzhou, China.
URL
https://www.china-boya.com/
IPO date
Mar 08, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,651,980
-3.87%
2,758,701
4.08%
Cost of revenue
1,921,688
2,038,769
Unusual Expense (Income)
NOPBT
730,291
719,933
NOPBT Margin
27.54%
26.10%
Operating Taxes
105,563
86,514
Tax Rate
14.45%
12.02%
NOPAT
624,728
633,419
Net income
237,466
-45.06%
432,198
25.45%
Dividends
(134,902)
(75,637)
Dividend yield
0.79%
0.41%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
32
24,988
Long-term debt
24,950
20,737
Deferred revenue
23,518
27,085
Other long-term liabilities
1
2
Net debt
(5,399,351)
(4,679,806)
Cash flow
Cash from operating activities
641,728
596,437
CAPEX
(87,496)
Cash from investing activities
14,252
Cash from financing activities
(236,650)
FCF
674,639
747,851
Balance
Cash
5,323,940
4,725,531
Long term investments
100,394
Excess cash
5,291,735
4,587,596
Stockholders' equity
3,261,671
3,225,672
Invested Capital
4,106,252
4,070,092
ROIC
15.28%
15.59%
ROCE
9.91%
9.86%
EV
Common stock shares outstanding
505,246
504,249
Price
33.68
-7.88%
36.56
-4.67%
Market cap
17,016,683
-7.70%
18,435,334
10.23%
EV
11,618,407
13,854,720
EBITDA
828,860
816,912
EV/EBITDA
14.02
16.96
Interest
801
623
Interest/NOPBT
0.11%
0.09%